ストックスクリーナーアプリを入手
11.75
3.37%
-0.41
アフターアワーズ：
11.83
0.08
+0.68%
Intellia Therapeutics Inc (NTLA) 最新ニュース
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - stocktwits.com
Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative
Does Priority Review Change The Bull Case For Intellia Therapeutics Stock (NTLA)? - simplywall.st
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Eastern Progress
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: A Look At Its 95.76% Potential Upside - directorstalkinterviews.com
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - Investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on FDA priority review - Investing.com
Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria
Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView
Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci
Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com
Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Australia
NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus
Why is Intellia Therapeutics stock rallying today? - Investing.com
Intellia stock rises on FDA priority review (NTLA:NASDAQ) - Seeking Alpha
NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z Review - GuruFocus
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance
Intellia Therapeutics stock jumps on FDA priority review - Investing.com
If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):